Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.

JW Therapeutics is a clinical stage cell therapy platform company, founded by Juno Therapeutics and WuXi AppTec in 2016, and focused on developing, manufacturing and commercialising breakthrough cell-based immunotherapies for hematological cancers and solid tumours.

The listing is the latest in the recent flurry of biotech IPOs in Hong Kong. Other recent issuers in the city include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Shearman team was led by partners Kyungwon (Won) Lee and Max Hua.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com

Related Articles

SG: Pinsents hires veteran energy lawyer from Shearman

by Mari Iwata |

Pinsent Masons MPillay, the Singapore office of UK law firm Pinsent Masons, has recruited senior energy and infrastructure expert David Clinch as a partner in Singapore from Shearman & Sterling, where he was an of counsel.

CC, Romulo, Shearman, V&A guide $3.9 bln Philippine network financing

by Mari Iwata |

Clifford Chance and Romulo Mabanta Buenaventura Sayoc & de los Angeles have advised the lenders on the $3.9 billion financing of Dito Telecommunity’s 4G and 5G telecommunications network in the Philippines, with Shearman and Sterling and Villaraza & Angangco advising Dito.

Shearman, AMT, White & Case, MHM act as Japan’s Benesse goes private for $1.78 bln

by Mari Iwata |

Shearman & Sterling and Anderson Mori & Tomotsune are advising Japanese educational services provider Benesse Holdings on a 270-billion-yen ($1.78 billion) management buyout (MBO) plan proposed by Swedish investment house EQT AB Group, represented by White & Case. Mori Hamada & Matsumoto act for the all stakeholders on this MBO scheme.